What is the significance of Merck's enlicitide decanoate receiving the FDA's new Commissioner’s National Priority Voucher?

Merck's cyclic peptide enlicitide decanoate was one of the first two drug candidates selected for the FDA's new Commissioner’s National Priority Voucher program, a pilot initiative designed to accelerate review to just 1–2 months—significantly faster than the 6 or more months required under other FDA priority review programs.

How does enlicitide decanoate work, and why is its potential approval considered groundbreaking for PCSK9 inhibitors?

Enlicitide is a cholesterol-lowering molecule that inhibits PCSK9, a protein that degrades receptors responsible for clearing low-density lipoproteins (LDL) from the blood; if approved, it would be the first PCSK9 inhibitor available as an oral pill, marking a major departure from existing injectable PCSK9 inhibitors.

Cyclic Peptides Gain Momentum in Drug Development

Jun 1, 2026

Merck's cyclic peptide enlicitide secured an FDA priority voucher, aiming to become the first oral PCSK9 inhibitor. Forecasts exceed $2 billion in annual sales, underscoring a rising trend in peptide-based pharmaceuticals.

cen

2026-05-07

Biocatalysts Build Big Molecule on Big Scale

2026-06-01

Cyclic Peptides Gain Momentum in Drug Development

Cyclic Peptides Gain Momentum in Drug Development

FAQ